Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD)
molecules that induce degradation by the ubiquitin-proteasome system (UPS) offer new …

Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle
challenging protein targets deemed undruggable with traditional small molecule inhibitors …

Biomarkers-guided precision therapeutics has revolutionized the clinical development and
administration of molecular-targeted anticancer agents. Tailored precision cancer therapy …

Abstract N6-methyladenosine (m6A) has emerged as an abundant modification throughout
the transcriptome with widespread functions in protein-coding and noncoding RNAs. It …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

The mitogen-activated protein kinase (MAPK) signaling pathway is the primary regulatory
module of various cellular processes such as cell proliferation, differentiation, and stress …